The Problem

The Solution

investment reasons

IMMUNIMED INC. is an Innovative, clinical stage Biopharmaceutical company developing Oral Antibodies to treat C Difficile Infection. We believe this treatment will become the new Standard of Care and generate over $1 B in annual revenue.

john hare and pradip maiti

John Hare (left), with Dr. Pradip K. Maiti, said, immunologists, including some doctors taking part in the clinical trial, are still incredulous about results from some of the compassionate trials that have produced full recovery and no recurrence. (Ruth Bonneville / Winnipeg Free Press)